



Published in final edited form as:

*J Ren Cancer*. 2020 ; 3(1): 20–33. doi:10.36959/896/604.

## A Comprehensive Analysis of the Effect of Histological Subtypes on the Survival Probability of Kidney Carcinoma Patients: A Hypertabastic Survival Analysis

Mohammad Tabatabai, PhD<sup>1,\*</sup>, Stephanie Bailey, MD<sup>1</sup>, Patricia Matthews-Juarez, PhD<sup>1</sup>, Habib Tabatabai, PhD<sup>2</sup>, Nader Bahri, MD<sup>1</sup>, Lyle Cooper, PhD<sup>1</sup>, Derek Wilus, MS<sup>1</sup>, Karan Singh, PhD<sup>3</sup>, Paul Juarez, PhD<sup>1</sup>

<sup>1</sup>Meharry Medical College, Nashville, USA

<sup>2</sup>University of Wisconsin Milwaukee, Milwaukee, USA

<sup>3</sup>University of Texas Health Sciences Center, Tyler, USA

### Abstract

The purpose of this study is two-fold. First, to find out whether the histological subtypes can serve as an independent prognostic factor for kidney carcinoma; and second, whether it's role can be maintained when we control for confounders. Using National Cancer Institute data from 1975-2016, we have modeled the impact of histological subtypes on the survival probability of kidney carcinoma patients. A total of 134,150 individuals were examined from the Surveillance, Epidemiology, and End Results program (SEER) [1]. The study variables are age, race/ethnicity, sex, tumor grade, type of surgery, geographical location of patient and stage of disease. We have applied the Hypertabastic proportional hazards survival model [2-6] to analyze the survival time of patients diagnosed with kidney carcinoma in order to explore the effect of histological subtypes on their survival probability. In particular, our intention was to assess the relationship between the histological subtypes and tumor stage, grade, and type of surgery. Our results indicated that histology plays an important role both when used as the sole predictor in the survival model ( $P < 0.001$ ), as well as when controlling for confounding variables ( $P < 0.001$ ).

### Keywords

Histological subtypes; Hypertabastic survival models; kidney carcinoma; tumor grade; tumor stage

### Background

Kidney carcinoma is caused when healthy cells in one or both kidneys begin to grow rapidly form a tumor. According to the American Cancer Society's prediction of new cases of

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

\*Corresponding author: Mohammad Tabatabai, PhD, Meharry Medical College, Nashville, TN 37208, USA.

Conflict of Interest

The authors have no conflicts of interests to declare.

kidney cancer, which include renal pelvis cancer in the United States for the year 2020, 14,830 of 73,750 patients are predicted to die [7]. Risk factors for developing kidney carcinoma includes, but is not limited to, hypertension, smoking, obesity, hepatitis C and presence of other kidney diseases [8]. There has been an increasing trend in the rate of new kidney cancers since 1990 [7]. In 2016, the incidence rate of kidney and renal pelvis cancers was 16.8 per 100,000 people, which was ranked 9<sup>th</sup> among cancer incidence rates [9].

Histological differences play a significant role in prediction as well as diagnoses of kidney carcinoma and have a major impact in the survival time of such patients [10]. There are several types of kidney carcinoma including renal cell carcinoma (RCC), urothelial carcinoma, and sarcoma. RCC is the most common type, making up about 85% of diagnoses. Urothelial carcinoma, sometimes called transitional cell carcinoma, accounts for about 5-10% of diagnoses; whereas sarcoma is a rare type of kidney cancer accounting for less than 5% of all cases [11]. Within RCC, there are different histological subtypes, which are identified by a pathologist. Chromophobe RCC accounts for approximately five percent of RCC tumors [12]. This histological subtype is normally less aggressive when compared with the other types of RCCs. Chromophobe RCC tumors can become large, but tend to stay localized. There is no significant difference in the incidence rates of chromophobe RCC tumors between males and females, with the survival probability of this cancer being quite high [12,13]. Papillary RCC accounts for 10-15% of patients diagnosed with RCC [14]. Clear cell is the most common form of RCC.

Individuals who have been diagnosed with papillary RCC have lower risk of death, when compared to clear cell RCC [15]. Sarcomatoid RCC tends to grow more quickly than other types of kidney cancer. This rapid growth, makes the treatment more difficult and increases the likelihood of becoming a metastatic cancer [16]. Kang, et al. analyzed the conditional survival probability of patients with distant RCC who were treated with tyrosine kinase inhibitor therapy and identified predictors of conditional survival [17]. Prognostic influence of histological subtypes and grading on the survival probability of RCC patients have long been studied in literature [18-20]. Genomic and survival data analyses were used to find the association between sirtuin family members and clear cell RCC [21]. Nguyen, et al. investigated the effect of histological subtypes on the survival of patients diagnosed with RCC, and found histological subtypes to be an important prognostic factor [22,23]. Hematology and histology play a vital role as predictive measures of RCC [24]. Teloken, et al. evaluated the effect of histological subtypes on patients diagnosed with localized RCC and concluded that clear cell RCC was a prognostic factor for patients who underwent surgery [25]. Kappa statistics were used to investigate the concordance between tumor histological subtypes at their original point of diagnosis and after slide revision [26]. A study by Cai, et al. investigated the effect of age on the survival probability of patients with localized RCC who underwent radical nephrectomy and found older age is associated with lower survival probability [27]. Carrasco, et al. studied the impact of histology on the survival of patients diagnosed with distant RCC who underwent cytoreductive nephrectomy [28], and Wagner, et al. compared the risk of death of clear cell RCC patients with those diagnosed with papillary RCC [15]. Both Carrasco and Wagner found the significance of histological subtypes in the treatment of RCC patients. In our study, we have analyzed the impact of histological subtypes on the survival probability of patients diagnosed with

kidney carcinoma from 1975 to 2016 using the Hypertabastic proportional hazards model [2-6]. This parametric method is flexible and can accommodate different hazard shapes, and enable the researcher to better understand the effect of histological subtypes on the survival time of kidney carcinoma patients. Study results will be used to train medical students in understanding the extent of histological subtypes as a prognostic factor for patients diagnosed with kidney carcinoma.

## Methods

The clinical, socio-economic, and histological study variables were age, race/ethnicity, sex, tumor grade, type of surgery, geographical location of patient, and stage of disease. This retrospective study examined a total of 134,150 individuals from the Surveillance, Epidemiology, and End Results program (SEER) data base of whom 85,324 were males and 48,826 were females. We applied the univariable and multivariable Hypertabastic proportional hazards survival model to analyze the survival time of patients diagnosed with kidney carcinoma. In addition, the complex relationship between histological subtypes and the study variables were examined. The histological subtypes were classified using methods provided by the International Classification of Diseases on Oncology, Third Edition (ICD-O-3). The following software were used: SAS 9.4, SPSS 26, ggplot2 in R Studio 1.3.1073, and Mathematica 12.

## Results

A review of our data indicated that the overall mean (SD) and median age for our cohort was 61.51 (12.59) and 62 years respectively. The mean (SD) and median ages were 61.29 (12.23) and 62 years for males, and 61.89 (13.19) and 63 years for females, respectively. There was a significant difference in mean age between male and females (P-value < 0.001). Data revealed 57.8% of patients had adeno carcinoma with mixed subtype, 19.7% had papillary adeno carcinoma NS, 11.1% suffered from clear cell adeno carcinoma, 3.9% had renal cell adeno carcinoma, 2.5% were identified as having chromophobe RCC, 1.1% had sarcomatoid RCC, and only 0.7% were diagnosed with granular cell carcinoma. These seven histological subtypes included approximately 97% of the individuals in our study. The remaining 59 histological subtypes accounted for only 3% of the study's patients and their group is named "other histological types." Table 1 provides the name of all histological subtypes considered in this study together with their corresponding frequency and median survival time.

For all histological subtypes considered in our study, the percentage of males was higher than females (almost twice as high in males as in females in most cases). For instance, among individuals diagnosed with clear cell adenocarcinoma, 38.1% were female and 61.9% were male. For both males and females, clear cell adenocarcinoma had the highest percentage among the histological subtypes (60.5% female and 56.3% male). Among males and females with kidney carcinoma, 40.66% and 42.4% had clear cell adenocarcinoma and were White respectively. Among males and females with kidney carcinoma, 8.61% and 9.8% had clear cell adeno carcinoma and were Hispanic respectively. Among males and females with kidney carcinoma, 3.49% and 5.0% had clear cell adenocarcinoma and were AA/Black respectively. Among males and females with kidney carcinoma, 3.52% and 3.2%

had clear cell adenocarcinoma and were Asian respectively. Figure 1 illustrates the racial distribution of eight histological subtypes for males and females.

The stage of tumor helps in understanding the seriousness of kidney carcinoma. It improves estimation of prognosis and will eventually assist health care providers in their plan of treatment in order to increase the survival of their patients. Our data revealed that 74% of patients had localized, 17.3% had regional, and 8.7% had distant tumor stage. As indicated in Table 2, within all tumor stages, the majority of patients were diagnosed with clear cell adenocarcinoma. Within localized tumor stage, the lowest percentage of patients were diagnosed with sarcomatoid RCC; and within regional tumor stage, the lowest percentage belonged to granular cell carcinoma. Chromophobe RCC and granular cell carcinoma had the lowest percentages of patients within distant tumor stage. With the exception of sarcomatoid RCC, the number of patients diagnosed with localized tumor stage was the highest among all histological subtypes. Among sarcomatoid RCC patients, the percentage diagnosed with distant tumor stage was the highest.

The racial composition of our patients' data is comprised of 13.3% Hispanic, 5% Asian/Pacific Islanders, 11.2% African American, and 70.5% White. Among African Americans, the percentage of patients diagnosed with clear cell adeno carcinoma was highest, followed by papillary adenocarcinoma NOS, and renal cell adenocarcinoma; however, granular cell carcinoma had the lowest percentage, as seen in Table 3. Among Whites, Asian/Pacific Islanders, and Hispanics, the percentage of patients diagnosed with clear cell adeno carcinoma was highest, followed by renal cell adenocarcinoma. The lowest percentage among these three racial groups was granular cell carcinoma. Although the percentage of patients diagnosed with clear cell adenocarcinoma for all racial groups was highest when compared with all histological subtypes, the percentages of Whites, Asian/Pacific Islanders, and Hispanics were approximately 1.6, 1.9, and 1.9 times higher than that of African Americans, respectively. Among all racial groups, African Americans had the lowest percentage of clear cell adeno carcinoma. Although African Americans only accounted for 11.2 percent of our data, they were vastly overrepresented in those diagnosed with papillary adenocarcinoma as well as those with adenocarcinoma with mixed subtypes.

The regional distribution of patients residing in the Pacific Coast, East, Northern Plains, and Southwest was 45.5%, 39.4%, 10.8%, and 4.4% respectively. The percentage of patients diagnosed with clear cell adeno carcinoma across all regions were at least 50%; whereby the lowest percentage across all regions belonged to patients who were diagnosed with granular cell carcinoma. As shown in Table 4, the majority of patients diagnosed with renal cell adeno carcinoma were from the East region. Within granular cell carcinoma patients, 27.3% were from the East region, whereas 57% were from the Pacific Coast region. East had the highest percentage of renal cell adenocarcinoma, papillary adeno carcinoma NOS, and other histological subtypes; whereas Pacific Coast had the highest percentage for the remaining subtypes.

The distribution of tumor grade was as follows: 50.6% moderately differentiated, 28.2% poorly differentiated, 13.5% well differentiated, and 7.6% undifferentiated. Among all tumor grades, clear cell adeno carcinoma had the highest percentage of patients, followed

by renal cell adeno carcinoma. For all tumor grades except undifferentiated, papillary adenocarcinoma had the third highest percentage of patients. For undifferentiated tumor grade, the highest percentage belonged to clear cell adenocarcinoma followed by renal cell carcinoma and sarcomatoid RCC, respectively. For all histological subtypes, with the exception of sarcomatoid RCC and the Other histological types group, the percentage of patients who had moderately differentiated tumor grade was highest. For sarcomatoid RCC, the highest percentage belonged to undifferentiated grade; and for Other histological types group, poorly differentiated grade had the highest percentage. For adeno carcinoma patients with mixed subtypes, sarcomatoid RCC, granular cell carcinoma, and the Other histological types group, the well differentiated tumor grade had the lowest percentage. With regard to papillary adenocarcinoma, clear cell adeno carcinoma, renal cell adenocarcinoma, and chromophobe RCC, the undifferentiated tumor grade had the lowest percentage, as indicated in Table 5.

The distribution of surgery types were as follows: 4% had no surgery, 1% had cryosurgery 13 (local tumor destruction, NOS), 0.6% had thermal ablation, 1% had cryosurgery 23 (any combination of local tumor excision, polypectomy, or excisional therapy, NOS), 27.5% had partial nephrectomy or partial ureterectomy, 7.9% had complete nephrectomy, 55.7% had radical nephrectomy, 1% had any nephrectomy, 0.9% had nephrectomy, ureterectomy, and 0.7% had other types of surgery. With regard to all types of surgery, clear cell adenocarcinoma had the highest percentage. Within each histological subtype, radical nephrectomy had the highest percentage across all types of surgery, as shown in Table 6.

In the univariate Hypertabastic survival analyses, all factors were found to be independently significant (all  $P < 0.001$ ). However, in the multivariable model, age, race, histology, stage, region, grade, and surgery type remained statistically significant ( $P < 0.001$ ), with the exception of sex ( $P = 0.306$ ). African Americans had significantly lower survival probabilities followed by Hispanics, Asian/Pacific Islanders and Whites. There was no statistically significant difference between survival probability of Asian/Pacific Islanders and Whites ( $P = 0.208$ ). African Americans had the highest percentage among all racial groups in the following histological types: Papillary adenocarcinoma (27.2%), renal cell adenocarcinoma (21.4%), chromophobe RCC (4.7%), adenocarcinoma with mixed subtypes (4.6%), and other carcinomas (4.2%). In addition, African Americans had the highest percentage of no surgery (4.7%), complete nephrectomy (8.8%), nephrectomy/ureterectomy (1%), poorly differentiated (30.1%) cancer type, and localized (81.1%) tumor stage within race. Asian/Pacific Islanders had the highest distant (10.2%) tumor stage, while Hispanics had the highest regional (18.4%) tumor stage. The 5-year overall percentage of patients who survived was 93.8%. Figure 2 shows the survival probability curves as a function of survival time and the 3D survival probabilities as a function of survival time and age for eight histological subtypes. Sarcomatoid RCC (HR: 4.342, CI: 3.982-4.735) had the worst prognosis, followed by other (HR: 3.278, CI: 2.863-3.754), adeno with mixed subtypes (HR: 2.61 CI: 2.374-2.869), renal cell carcinoma (HR: 2.371, CI: 2.227-2.524), granular cell (HR: 2.251, CI: 1.256-2.590), papillary (HR: 1.925, CI: 1.772-2.091), clear cell adeno (HR: 1.863, CI: 1.753-1.980). The chromophobe RCC patients had the best probability of

survival. All hazard ratios were calculated with respect to chromophobe RCC, as indicated in Figure 2.

Similarly, Figure 3 illustrates the survival probabilities and hazard ratios for tumor stage. Distant stage had the worst probability of survival, followed by regional. The best survival probability was for the localized tumor stage. The slope of the survival curve for patients diagnosed with distant stage is much higher when compared with regional stage and localized stage. This is reflected in the distant (HR: 14.04, CI: 13.515-14.585) and regional (HR: 3.391, CI: 3.261-3.523) stage hazard ratios, using localized stage as a reference. Patients with distant tumor stage had a 14.04-fold higher rate of death when compared to patients with localized tumor stage.

Figure 4 displays the survival probabilities and hazard ratios for tumor grade. Disease grade played an important role in determining the patient survival probabilities. The median survival time for well differentiated, moderately differentiated, poorly differentiated, and undifferentiated were 72, 62, 44, and 29 months respectively. Hazard ratios of moderately differentiated, poorly differentiated, and undifferentiated grade are 1.193 (CI: 1.102-1.291), 2.131 (CI: 2.049-2.216), and 3.244 (CI: 3.029-3.475), with respect to well differentiated grade.

The hazard ratio of undifferentiated to well differentiated tumor grade was 3.244.

Figure 5 reveals that cryosurgery 13 (HR: 1.318, CI: 0.882-1.971), thermal ablation (HR: 1.690, CI: 1.086-2.631), cryosurgery 23 (HR: 1.772, CI: 1.275-2.463), other types of surgery (HR: 2.089, CI: 1.753-2.489), nephrectomy/ureterectomy (HR: 2.392, CI: 1.949-2.935), complete nephrectomy (HR: 2.515, CI: 2.122-2.981), radical nephrectomy (HR: 3.026, CI: 2.574-3.557), any nephrectomy (HR: 3.608, CI: 3.003-4.335), and no surgery (HR: 8.849, CI: 7.480-10.469) had higher risk of death with respect to patients treated with partial nephrectomy or partial ureterectomy. By far, patients that did not undergo surgery had the worst survival probability. The speed of decline in survival probability for those patients who refused surgery was highest, when compared with those who had any type of surgery at every time point. For every 100 deaths associated with patients who underwent partial nephrectomy or ureterectomy, there will be 885 deaths associated with patients who did not undergo any type of surgery.

In spite of region being an overall significant factor ( $P < 0.001$ ), a further examination of Figure 6 reveals that there was no significant difference in survival probability in East and Southwest. In addition, there was no significant difference between the survival probability of patients living in Northern Plains and Pacific Coast. Southwest, East, and Pacific Coast hazard ratios are 1.071 (CI: 0.990-1.159), 1.055 (CI: 0.985-1.130), and 1.019 (CI: 0.953-1.090), relative to Northern Plains.

Survival curves and hazard ratios for racial groups are shown in Figure 7. The lowest survival probability belonged to African Americans (HR: 1.15, CI: 1.094-1.208), followed by Hispanics (HR: 1.084, 1.037-1.134), Asian/Pacific Islanders (HR: 1.043, 0.977-1.113), and Whites. There was a significant difference between Hispanics and Whites ( $P$ -value  $< 0.001$ ) as well as African Americans and Whites ( $P$ -value  $< 0.001$ ). Figure 8 illustrates a

summary forest plot of hazard ratios and their corresponding 95% confidence intervals for all categorical variables.

A comparison of median survival times of all categories of model variables, revealed that patients who did not undergo any type of surgery had the lowest median survival time, as indicated by Figure 9. The next lowest median survival time belonged to patients who had sarcomatoid RCC followed closely by individuals who had distant tumor stage. By far, patients who were diagnosed with granular cell carcinoma had the highest median survival time. The 5- and 10- year survival probabilities are depicted for a typical male living in the East region diagnosed with distant stage, undifferentiated grade, and underwent partial nephrectomy or partial ureterectomy surgery, embodied in Table 7.

Male patients diagnosed with sarcomatoid RCC, as indicated in Table 7, had the worst probability of survival among all histological subtypes and all racial groups. The 5- and 10-year survival probabilities for sarcomatoid RCC were [Asian/Pacific Islanders = (0.209, 0.073), Hispanics = (0.196, 0.065), African Americans = (0.178, 0.056), Whites = (0.223, 0.081)]; however, the difference in survival probabilities across racial groups were not significant. African Americans had the lowest survival probability for both 5- and 10- year, when diagnosed with sarcomatoid RCC, and Whites had the highest.

Similarly, Table 8 shows the 5- and 10-year survival probabilities for a typical male living in the East region diagnosed with localized stage, well differentiated grade, and underwent partial nephrectomy or partial ureterectomy surgery; and the survival probabilities were above 93% across all histological subtypes and racial groups. In addition, the survival probabilities for females under the same conditions as males seen in Table 7 and Table 8 had similar results and were excluded from this paper.

Table 9 describes the survival probabilities of male patients living in the East region diagnosed with localized stage, poorly differentiated grade, and underwent radical nephrectomy. Although not shown here, similar results were found for females.

## Discussion

Our analysis of the 134,150 patients who were diagnosed with kidney carcinoma in the United States revealed that histological subtypes play an important role both when used as the sole predictor in the survival model, as well as when controlling for confounding variables. Within all histological subtypes, the majority of patients were diagnosed with clear cell adenocarcinoma (57.8%). Among African American patients, 27.2% were diagnosed with papillary adenocarcinoma NOS, while among Whites, the percentage was 10.1%. In all four regions, the percentage of patients who had clear cell adeno carcinoma were above 50%. Stage was a significant factor with regard to patients' survival time being 64 months for localized, 43 months for regional, and 11 months for distant. As expected, the survival rate was lowest for patients diagnosed with distant stage [29]. The majority of patients within tumor stage were diagnosed with clear cell adeno carcinoma. Although the percentage of patients diagnosed with clear cell adenocarcinoma for all racial groups was highest when compared with all histological subtypes, the percentages of Whites, Asian/

Pacific Islanders, and Hispanics were approximately 1.6, 1.9, and 1.9 times higher than that of African Americans, respectively.

Differences in survival probability, with respect to histological subtypes, can be attributed to several different factors affecting survival. For instance, sarcomatoid RCC is associated with high tumor grade, which can worsen the overall prognosis of patients; chromophobe RCC tends to have a larger cell structure, therefore making it easier to diagnose; and clear cell RCC is infiltrated by a larger number of T cells, resulting in a greater immune response [30-32]. Sarcomatoid RCC patients had a very low survival probability when compared to chromophobe RCC patients. For every 100 deaths due to chromophobe RCC, there will be 434 deaths for sarcomatoid RCC at each time point. Most studies have concentrated on a small number of histological subtypes [22,28,33]. Those afflicted with sarcomatoid RCC had the lowest median survival time of any other category other than those who had no surgery. Data showed patients with this histological subtype tend to be associated with regional and distant stages, suggesting that patients are diagnosed late or are difficult to diagnose [30]. Clear cell adenocarcinoma is by far the leading cancer type in our study, accounting for over half of all patients. The authors suggest more research should be done on these subtypes due to their severity and large frequency.

In the univariate analysis, sex was a significant factor ( $P < 0.001$ ); but in the multivariable model, when controlling for potential confounders, the effect of sex disappeared ( $P < 0.306$ ). Similar results were previously observed [34]. Our results indicated that Whites had the highest probability of surviving death due to kidney carcinoma, followed by Asian/Pacific Islanders and Hispanics. African Americans had the lowest overall survival probabilities. Among histological subtypes, chromophobe renal cell adeno carcinoma had the highest survival probability followed by clear cell adenocarcinoma. The lowest survival probability was associated with sarcomatoid RCC.

This study obtained appropriate variables from a database consistently maintaining current and reliable big data. Furthermore, the results will help to further research in needed areas. The Hypertabastic survival model used here has flexibility in shaping hazard curves when compared to classical models [3,6]. Identification of histological subtypes are important in prognosis and precision medicine [35]. One of the limitations in this study is that patients in the SEER database tend to be urban and belong to a lower socioeconomic status [36]. To assess the risk associated with different combinations of factors, we have provided a R program in the supplementary material section. The authors believe that this paper will assist health care providers in making wise decisions in the future treatment of kidney carcinoma patients by examining the risk associated with different combinations of age, race/ethnicity, sex, tumor grade, type of surgery, geographical location of patient, and stage of disease.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.




## Acknowledgement

The project has been supported by Meharry Medical College RCMI grant (NIH grant MD007586). This project has also been partially supported by HRSA under grant number UH-1HP30348. This information or content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by RCMI or HRSA.


## References

1. (2019) Surveillance, epidemiology, and end results program. National Cancer Institute, DCCPS, Surveillance Research Program.
2. Tabatabai MA, Eby WM, Nimeh N, et al. (2012) Clinical and multiple gene expression variables in survival analysis of breast cancer: Analysis with the hypertabastic survival model. *BMC Med Genomics* 5: 63. [PubMed: 23241496]
3. Tahir MR, Tran QX, Nikulin MS. (2017) Comparison of hypertabastic survival model with other unimodal hazard rate functions using a goodness-of-fit test. *Stat Med* 36: 1936–1945. [PubMed: 28173610]
4. Tabatabai MA, Bursac Z, Williams DK, et al. (2007) Hypertabastic survival model. *Theor Biol Med Model* 4: 40. [PubMed: 17963492]
5. Tabatabai MA, Eby WM, Nimeh N, et al. (2012) Role of metastasis in hypertabastic survival analysis of breast cancer: Interaction with clinical and gene expression variables. *Cancer Growth Metastasis* 5: S8821.
6. Nikulin M, Wu HDI (2016) *The cox model and its applications*. Springer Berlin Heidelberg.
7. (2020) Key statistics about kidney cancer.
8. Lee JE, Mannisto S, Spiegelman D, et al. (2009) Intakes of fruit, vegetables, and carotenoids and renal cell cancer risk: A pooled analysis of 13 prospective studies. *Cancer Epidemiology Biomarkers Prevention* 18: 1730–1739.
9. (2020) USCS Data Visualizations.
10. Tabibu S, Vinod PK, Jawahar CV (2019) Pan-renal cell carcinoma classification and survival prediction from histopathology images using deep learning. *Sci Rep* 9: 10509. [PubMed: 31324828]
11. Srigley JR, Delahunt B, Eble JN, et al. (2013) The international society of urological pathology (isup) Vancouver classification of renal neoplasia. *Am J Surg Pathol* 37: 1469–1489. [PubMed: 24025519]
12. Baharzadeh F, Sadeghi M, Ramezani M (2019) Chromophobe renal cell carcinoma or oncocytoma: A manner of challenge in frozen section diagnosis. *BioMedicine* 9: 6. [PubMed: 30794153]
13. Amin MB, Paner GP, Alvarado-Cabrero I, et al. (2008) Chromophobe renal cell carcinoma: Histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. *Am J Surg Pathol* 32:1822–1834. [PubMed: 18813125]
14. Cairns P (2010) Renal cell carcinoma. *Cancer Biomark* 9: 461–473. [PubMed: 22112490]
15. Wagener N, Edelmann D, Benner A, et al. (2017) Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease. *PLoS One* 12: e0184173. [PubMed: 28934212]
16. Golshayan AR, George S, Heng DY, et al. (2009) Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor–targeted therapy. *J Clin Oncol* 27: 235–241. [PubMed: 19064974]
17. Kang M, Park JY, Jeong CW, et al. (2018) Changeable conditional survival rates and associated prognosticators in patients with metastatic renal cell carcinoma receiving first line targeted therapy. *J Urol* 200: 989–995. [PubMed: 29940249]
18. Gudbjartsson T, Hardarson S, Petursdottir V, et al. (2005) Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: A retrospective nation-wide study of 629 patients. *Eur Urol* 48: 593–600. [PubMed: 15964127]
19. Abdel-Rahman O (2018) Impact of histological subtype on outcomes of renal cell carcinoma patients. *Journal of Drug Assessment* 7:14–20.


20. Strauss A, Uhlig J, Lotz J, et al. (2019) Tumor laterality in renal cancer as a predictor of survival in large patient cohorts: A STROBE compliant study. *Medicine* 98: e15346. [PubMed: 31027111]
21. Tan Y, Li B, Peng F, et al. (2020) Integrative analysis of sirtuins and their prognostic significance in clear cell renal cell carcinoma. *Front Oncol* 10: 218. [PubMed: 32158696]
22. Nguyen DP, Vertosick EA, Corradi RB, et al. (2016) Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy. *Urol Oncol* 34: 259.e1–259.e8.
23. Patard J-J, Leray E, Rioux-Leclercq N, et al. (2005) Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. *J Clin Oncol* 23: 2763–2771. [PubMed: 15837991]
24. Grivas N, Hastazeris K, Kafarakis V, et al. (2014) Clinico-pathological prognostic factors of renal cell carcinoma: A 15-year review from a single center in Greece. *Urol Ann* 6: 116–121. [PubMed: 24833821]
25. Teloken PE, Thompson RH, Tickoo SK, et al. (2009) Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. *J Urol* 182: 2132–2136. [PubMed: 19758615]
26. Ficarra V, Martignoni G, Galfano A, et al. (2006) Prognostic role of the histologic subtypes of renal cell carcinoma after slide revision. *Eur Urol* 50: 786–794. [PubMed: 16697521]
27. Cai M, Wei J, Zhang Z, et al. (2012) Impact of age on the cancer-specific survival of patients with localized renal cell carcinoma: Martingale residual and competing risks analysis. *PLoS One* 7: e48489. [PubMed: 23119034]
28. Boorjian S, Carrasco A, Thompson Rh, et al. (2014) The impact of histology on survival for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. *Indian J Urol* 30: 38. [PubMed: 24497680]
29. Pärn M-L, Innos K, Baburin A, et al. (2019) Gastric cancer trends in Estonia 1995–2014 by age, subsite, morphology and stage. *Acta Oncol* 58: 283–289. [PubMed: 30632855]
30. Shuch B, Bratslavsky G, Linehan WM, et al. (2012) Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. *Oncologist* 17: 46–54. [PubMed: 22234634]
31. Vera-Badillo FE, Conde E, Duran I (2012) Chromophobe renal cell carcinoma: A review of an uncommon entity: Chromophobe renal cell carcinoma. *Int J Urol* 19: 894–900. [PubMed: 22715810]
32. Hsieh JJ, Purdue MP, Signoretti S, et al. (2017) Renal cell carcinoma. *Nat Rev Dis Primers* 3: 17009. [PubMed: 28276433]
33. Amin MB, Corless CL, Renshaw AA, et al. (1997) Papillary (chromophil) renal cell carcinoma: Histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. *Am J Surg Pathol* 21: 621–635. [PubMed: 9199639]
34. May M, Aziz A, Zigeuner R, et al. (2013) Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: An analysis of the multicenter CORONA database. *World J Urol* 31:1073–1080. [PubMed: 23568445]
35. Muglia VF, Prando A (2015) Renal cell carcinoma: Histological classification and correlation with imaging findings. *Radiol Bras* 48: 166–174. [PubMed: 26185343]
36. Kuo T-M, Mobley LR (2016) How generalizable are the SEER registries to the cancer populations of the USA? *Cancer Causes Control* 27: 1117–1126. [PubMed: 27443170]




**Figure 1:**  
Racial distribution based on histological subtypes and sex.




**Figure 2:** 2D and 3D survival curves and hazard ratios for histological subtypes.




**Figure 3:** 2D and 3D survival curves and hazard ratios for Stage.



**Figure 4:** Survival curves hazard ratios for Grade.




**Figure 5:** Survival probability hazard ratios for Surgery.




**Figure 6:** Survival probabilities hazard ratios for Region.






**Figure 7:** Survival probabilities hazard ratios for Race.



**Figure 8:** Forest plot of hazard ratios with 95% confidence intervals.



**Figure 9:**  
Forest plot for median survival time.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 1:**

Frequencies and median survival times for patients with indicated histological subtypes.

ICD-O-3 Code	Text Description	Freq	Median Survival (Month)	ICD-O-3 Code	Text Description	Freq	Median Survival (Month)
8310	Clear Cell Adeno/Ca	77547	52	8020	Undifferentiated Carcinoma	11	2
8312	Renal Cell Adeno/Ca	26368	73	8021	Anaplastic Carcinoma	6	4.5
8260	Papillary Adeno Ca NOS	14860	52	8481	Mucin Prod Ca/Adenoc	6	17
8317	Chromophobe Renal Cell Ca	5174	65	8280	Acidophil Ca/Adenoc	5	107
8255	Adeno CA w/mixed subtypes	3332	37	8313	Clear cell Adeno carcino fibroma	5	20
8318	Sarcomatoid Renal Cell Ca	1505	9	8013	Lg Cell Neuroendocrine Carc	4	9.5
8320	Granular Cell Carcinoma	990	98	8342	Pap Carcinoma Oxyphilic cell	4	39
8120	Transitional Cell Carcinoma	936	12	8074	Squam Cell Ca Spindle Cell	3	3
8316	Cyst-assoc renal cell Ca	796	81	8230	Solid Carcinoma NOS	3	94
8130	Papillary Transitional Cell Ca	691	47	8504	Intracyst Pap Aden/Ca	3	149
8319	Collecting Duct Carcinoma	314	17	8560	Adeno squamous Carcinoma	3	5
8050	Papillary Squamous Cell Carc	286	78	8022	Pleomorphic Carcinoma	2	73.5
8010	Carcinoma NOS	237	5	8031	Giant Cell Carcinoma	2	51
8140	Adeno Carcinoma NOS	225	19	8052	Papillary Carcinoma	2	34
8323	Mixed Cell Carcinoma	133	52	8072	Squamous Cell Ca non-Kerit	2	5.5
8270	Chromophobe Adeno/Ca	101	72	8131	Micropapillary Transintl Cell Ca	2	34
8290	Oncocytic Adeno/Ca	96	68.5	8190	Trabecular Adeno/Ca	2	123
8070	Squamous Cell Carcinoma	81	6	8330	Follicular Adeno/Ca	2	53
8033	Pseudosarcomatous Carcinoma	55	5	8522	Mix Duct & Lobular Ca	2	9
8510	Medullary Adeno/Ca	47	7	8574	Aden/Ca; Neuroendocrine diff	2	5.5
8211	Tubular Adeno/Ca	44	93	8030	Giant & Spindle Cell Carc	1	NA
8480	Mucinous Ca/Adenoc	44	26.5	8076	Squam Cell Ca: Microinvasive	1	NA
8246	Neuroendocrine Ca	33	22	8083	Basaloid Squamous Cell Carc	1	NA
8041	Small Cell Carcinoma NOS	28	6	8210	Adenoca in Aden Polyp	1	NA
8032	Spindle Cell Carc	22	10	8249	Atypical Carcinoid Tumor	1	NA
8240	Carcinoid Tumor	21	67	8251	Alveolar Adeno/Ca	1	NA

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

ICD-O-3 Code	Text Description	Freq	Median Survival (Month)	ICD-O-3 Code	Text Description	Freq	Median Survival (Month)
8263	Adenoca in Tubulovill Ad	21	101	8315	Glycogen-Rich Carc	1	NA
8046	Non-Small Cell Carc	19	2	8325	Metanephric adenoma	1	NA
8071	Squamous Cell Ca Keratiniz	17	9	8440	Cystadenocarcinoma NOS	1	NA
8550	Acinic Cell Adeno/Ca	17	99	8490	Signet Ring Cell Adeno/Ca	1	NA
8122	Spindle Cell Transitional Cell Ca	15	6	8500	Duct Adeno/Ca	1	NA
8012	Large Cell Carcinoma NOS	12	7	8503	Intraduct Pap Adeno/Ca	1	NA

**Table 2:**

Kidney Carcinoma Histological Subtypes by Tumor Stage.

	Localized		Regional		Distant	
	% Within Hist	% Within Tumor	% Within Hist	% Within Tumor	% Within Hist	% Within Tumor
<b>Adeno carcinoma with mixed type</b>	66.1	2.2	18.8	2.7	15.1	4.3
<b>Papillary adeno carcinoma NOS</b>	85.6	12.8	11.2	7.1	3.3	4.2
<b>Clear cell adeno carcinoma</b>	74.6	58.2	17.8	59.3	7.7	51.2
<b>Renal cell adeno carcinoma</b>	71.7	19.0	17.4	19.8	10.9	24.6
<b>Chromophobe RCC</b>	83.9	4.4	13.9	3.1	2.1	0.9
<b>Sarcomatoid RCC</b>	18.1	0.3	34.8	2.3	47.2	6.1
<b>Granular cell carcinoma</b>	66	0.7	23.90	1.0	10.10	0.9
<b>Other histological subtypes</b>	54.1	2.4	25.2	4.8	20.7	7.8

\* Percentages may not add up to 100% due to rounding.

Kidney carcinoma histological subtypes by race.

**Table 3:**

	African Americans		Whites		Asian/Pacific Islanders		Hispanics	
	% Within Hist	% Within Race	% Within Hist	% Within Race	% Within Hist	% Within Race	% Within Hist	% Within Race
Adenocarcinoma with mixed type	20.9	4.6	63.9	2.3	4.5	2.2	10.7	2.0
<b>Papillary adenocarcinoma NOS</b>	27.6	27.2	64.1	10.1	2.8	6.1	5.6	4.6
Clear cell adenocarcinoma	7.0	36.1	71.4	58.6	5.9	68.3	15.6	67.9
<b>Renal cell adenocarcinoma</b>	12.2	21.4	71.9	20.1	3.8	14.9	12.0	17.8
Chromophobe RCC	13.8	4.7	69.5	3.8	4.7	3.6	12.0	3.5
Sarcomatoid RCC	9.5	0.9	70.6	1.1	6.1	1.4	13.8	1.2
Granular cell carcinoma	10.8	0.7	73.4	0.8	4.2	0.6	11.5	0.6
<b>Other histological subtypes</b>	14.6	4.2	71.2	3.3	4.4	2.9	9.8	2.4
Adenocarcinoma with mixed type	20.9	4.6	63.9	2.3	4.5	2.2	10.7	2.0
<b>Papillary adenocarcinoma NOS</b>	27.6	27.2	64.1	10.1	2.8	6.1	5.6	4.6

\* Percentages may not add up to 100% due to rounding

**Table 4:**

Kidney carcinoma histological subtypes by region.

	East		Northern Plains		Pacific Coast		Southwest	
	% Within Hist	% Within Region	% Within Hist	% Within Region	% Within Hist	% Within Region	% Within Hist	% Within Region
Adenocarcinoma with mixed type	36.4	2.3	12.3	2.8	49.1	2.7	2.2	1.2
Papillary adenocarcinoma NOS	44.8	12.6	13.1	13.5	39.2	9.6	2.9	7.2
Clear cell adenocarcinoma	34.1	50.0	12.1	65.1	49.1	62.5	4.7	61.2
Renal cell adenocarcinoma	52.2	26.1	5.9	10.8	37.2	16.1	4.7	20.8
Chromophobe RCC	38.0	3.7	9.4	3.4	47.6	4.0	5.0	4.3
Sarcomatoid RCC	38.7	1.1	10.3	1.1	46.5	1.1	4.5	1.1
Granular cell carcinoma	27.3	0.5	10.4	0.7	57.0	0.9	5.4	0.9
Other histological subtypes	43.9	3.6	8.4	2.5	43.3	3.1	4.4	3.2
Adeno carcinoma with mixed type	36.4	2.3	12.3	2.8	49.1	2.7	2.2	1.2
Papillary adeno carcinoma NOS	44.8	12.6	13.1	13.5	39.2	9.6	2.9	7.2

\* Percentages may not add up to 100% due to rounding.



**Table 5:**

Kidney carcinoma histological subtypes by grade.

	Well Differentiated		Moderately Differentiated		Poorly Differentiated		Undifferentiated	
	% Within Hist	% Within Grade	% Within Hist	% Within Grade	% Within Hist	% Within Grade	% Within Hist	% Within Grade
Adenocarcinoma with mixed type	10.8	2.0	40.2	2.0	29.3	2.6	19.7	6.4
Papillary adenocarcinoma NOS	12.8	10.5	53.1	11.6	30.9	12.1	3.3	4.8
Clear cell adenocarcinoma	13.4	57.3	53.6	61.2	26.7	54.7	6.2	47.3
Renal cell adenocarcinoma	16.2	23.5	47.7	18.5	28.4	19.8	7.8	20.0%
Chromophobe RCC	8.4	2.4	54.3	4.1	31.6	4.3	5.6	2.9
Sarcomatoid RCC	1.7	0.1	4.9	0.1	27.3	1.1	66.1	9.7
Granular cell carcinoma	7.9	0.4	40.8	0.6	39.1	1.0	12.2	1.2
Other histological subtypes	15.5	3.7	28.5	1.8	38.0	4.4	18.0	7.7
Adeno carcinoma with mixed type	10.8	2.0	40.2	2.0	29.3	2.6	19.7	6.4
Papillary adeno carcinoma NOS	12.8	10.5	53.1	11.6	30.9	12.1	3.3	4.8

\* Percentages may not add up to 100% due to rounding

**Table 6:**

Kidney Carcinoma Surgical Type by Histological Subtypes.

	Adeno carcinoma with mixed type		Papillary adeno CA NOS		Clear cell adeno CA		Renal cell adeno CA		Chromophobe		Sarcomatoid RCC		Granular cell CA		Other histological types	
	% Within Hist	% Within Surgery	% Within Hist	% Within Surgery	% Within Hist	% Within Surgery	% Within Hist	% Within Surgery	% Within Hist	% Within Surgery	% Within Hist	% Within Surgery	% Within Hist	% Within Surgery	% Within Hist	% Within Surgery
No Surgery	2.2	1.4	2.4	6.6	3.0	43.3	6.4	31.6	1.1	1.0	10.9	3.1	3.2	0.6	15.0	12.4
Cryosurgery 13	0.7	1.9	1.2	14.3	1.1	64.3	0.8	16.6	0.4	1.7	0.1	0.1	0.3	0.2	0.3	0.9
Thermal ablation	0.3	1.2	0.8	15.6	0.7	67.0	0.4	13.4	0.3	2.1	0.0	0.0	0.0	0.0	0.1	0.8
Cryosurgery 23	0.7	1.7	1.1	12.7	1.1	64.0	0.9	17.7	0.5	2.0	0.0	0.0	1.1	0.8	0.3	1.1
Partial Nephrectomy/Ureterectomy	26.1	2.4	41.4	16.7	28.5	59.9	19.6	14.0	33.1	4.6	5.4	0.2	13.3	0.4	15.7	1.9
Complete Nephrectomy	7.1	2.3	7.9	11.1	7.5	55.0	7.5	18.7	7.6	3.8	5.3	0.8	6.6	0.6	18.7	7.8
Radical Nephrectomy	59.5	2.7	43.0	8.6	56.3	58.5	60.9	21.5	55.0	3.8	70.8	1.4	72.8	1.0	44.3	2.6
Any Nephrectomy	1.9	4.8	0.7	8.1	0.7	44.1	1.2	24.8	0.9	3.3	6.0	6.8	0.8	0.6	2.2	7.4
Nephrectomy, Ureterectomy	1.0	2.9	0.7	8.6	0.7	43.0	1.5	32.3	0.7	3.2	1.1	1.3	1.4	1.2	2.1	7.6
Other	0.5	1.9	0.8	13.0	0.5	46.4	1.0	28.7	0.4	2.3	0.5	0.9	0.4	0.5	1.3	6.3

\* Percentages may not add up to 100% due to rounding.

Survival probabilities for a typical male living in the East region diagnosed with distant stage, undifferentiated grade, and underwent partial nephrectomy or partial ureterectomy surgery.

**Table 7:**

Histological Subtype	Race/Ethnicity											
	Asian/PI		Hispanics		African American		Whites					
	5-YRS	10-YRS	5-YRS	10-YRS	5-YRS	10-YRS	5-YRS	10-YRS				
Adenocarcinoma With mixed subtypes	0.390	0.207	0.376	0.194	0.354	0.176	0.406	0.221				
Papillary Adenocarcinoma NOS	0.500	0.313	0.486	0.299	0.465	0.278	0.514	0.328				
Clear Cell Adenocarcinoma	0.511	0.325	0.497	0.310	0.477	0.289	0.525	0.340				
Renal Cell Adenocarcinoma	0.425	0.239	0.411	0.226	0.390	0.206	0.440	0.253				
Chromophobe Renal Cell Carcinoma	0.697	0.547	0.687	0.534	0.672	0.514	0.708	0.560				
Sarcomatoid Renal Cell Carcinoma	0.209	0.073	0.196	0.065	0.178	0.056	0.223	0.081				
Granula Cell Carcinoma	0.444	0.257	0.430	0.243	0.409	0.224	0.459	0.272				
Other Histological Subtypes	0.307	0.138	0.293	0.128	0.272	0.113	0.322	0.150				

Survival probabilities for a typical male living in the East region diagnosed with localized stage, well differentiated grade, and underwent partial nephrectomy or partial ureterectomy surgery.

**Table 8:**

Histological Subtype	Race/Ethnicity									
	Asian/PI		Hispanics		African American		Whites			
	5-YRS	10-YRS	5-YRS	10-YRS	5-YRS	10-YRS	5-YRS	10-YRS	5-YRS	10-YRS
Adenocarcinoma With mixed subtypes	0.980	0.966	0.979	0.965	0.977	0.963	0.980	0.967	0.985	0.976
Papillary Adenocarcinoma NOS	0.985	0.975	0.984	0.974	0.983	0.972	0.985	0.977	0.986	0.970
Clear Cell Adenocarcinoma	0.985	0.976	0.985	0.975	0.984	0.973	0.986	0.977	0.982	0.970
Renal Cell Adenocarcinoma	0.981	0.970	0.981	0.968	0.980	0.966	0.982	0.970	0.992	0.987
Chromophobe Renal Cell Carcinoma	0.992	0.987	0.992	0.986	0.991	0.985	0.992	0.987	0.992	0.987
Sarcomatoid Renal Cell Carcinoma	0.966	0.944	0.965	0.942	0.963	0.939	0.968	0.946	0.968	0.946
Granula Cell Carcinoma	0.982	0.971	0.982	0.969	0.981	0.968	0.983	0.972	0.983	0.972
Other Histological Subtypes	0.974	0.957	0.973	0.956	0.972	0.953	0.975	0.959	0.975	0.959

Survival probabilities for a typical male living in the East region diagnosed with localized stage, poorly differentiated grade, and underwent radical nephrectomy surgery.

**Table 9:**

Histological Subtype	Race/Ethnicity											
	Asian/PI		Hispanics		African American		Whites					
	5-YRS	10-YRS	5-YRS	10-YRS	5-YRS	10-YRS	5-YRS	10-YRS				
Adenocarcinoma With mixed subtypes	0.875	0.800	0.871	0.793	0.863	0.782	0.880	0.807				
Papillary Adenocarcinoma NOS	0.906	0.848	0.903	0.843	0.897	0.834	0.910	0.854				
Clear Cell Adenocarcinoma	0.909	0.853	0.906	0.847	0.900	0.839	0.913	0.858				
Renal Cell Adenocarcinoma	0.886	0.816	0.882	0.810	0.875	0.800	0.890	0.823				
Chromophobe Renal Cell Carcinoma	0.950	0.918	0.948	0.915	0.945	0.910	0.952	0.921				
Sarcomatoid Renal Cell Carcinoma	0.801	0.690	0.794	0.680	0.783	0.664	0.808	0.700				
Granula Cell Carcinoma	0.891	0.825	0.887	0.819	0.881	0.809	0.896	0.831				
Other Histological Subtypes	0.846	0.756	0.840	0.747	0.831	0.734	0.852	0.764				